2024-09-06 - Analysis Report
## JNJ Stock Analysis Report

**Company:** Johnson & Johnson (JNJ)

**Company Overview:**  Johnson & Johnson is a multinational healthcare company that develops, manufactures, and sells a wide range of pharmaceutical, medical device, and consumer healthcare products.

**1. Performance Comparison:**

* **Cumulative Return:** JNJ has a cumulative return of 20.84%, while the S&P 500 (VOO) has a cumulative return of 84.86%. 
* **Relative Deviation:** JNJ is lagging behind the S&P 500 by 69.78%. This places its performance at the 12.84th percentile of its historical performance range. 

**2. Recent Price Movement:**

* **Closing Price:** $167.36
* **5-Day Moving Average:** $165.71
* **20-Day Moving Average:** $161.94
* **60-Day Moving Average:** $154.86

JNJ is trading above its 5-day, 20-day, and 60-day moving averages, indicating a potential upward trend.

**3. Technical Indicators:**

* **RSI:** 86.39 (Overbought)
* **PPO:** 0.18 (Positive)
* **Delta_Previous_Relative_Divergence:** -9.44 (Short-term decline)
* **Expected Return:** 11.93% (5-year expected return on current investment)

JNJ is currently in overbought territory based on RSI, suggesting potential for a short-term correction. However, the positive PPO and the 11.93% expected return suggest a long-term positive outlook. 

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-07-25 | 1.95 | 22.45 B$ |
| 2024-05-01 | 1.35 | 21.38 B$ |
| 2024-02-16 | 1.68 | 21.39 B$ |
| 2023-10-27 | 10.32 | 21.35 B$ |
| 2024-02-16 | 10.32 | 21.35 B$ |

Johnson & Johnson's recent earnings have shown consistent revenue growth. However, EPS has been volatile. While the most recent earnings report for the quarter ending July 25th has not yet been released, analysts are expecting an EPS of $2.12 and a revenue of $22.85B. 

**5. Overall Analysis:**

JNJ is currently trading above its moving averages and has a positive expected return. However, the stock is in overbought territory based on its RSI, suggesting potential for a short-term correction. The company's recent earnings have been relatively stable with consistent revenue growth. 

**6. Conclusion:**

While JNJ shows a potential for long-term growth, the current overbought condition and recent lagging performance compared to the S&P 500 might warrant a cautious approach for short-term investors. However, the long-term outlook remains positive, with consistent revenue growth and a favorable expected return. Further analysis of the upcoming earnings report for the quarter ending July 25th will provide further insight into the company's future performance. 
